MedTrace Logo

Comparison of Intermittent Bolus vs. Continuous Infusion PENG Block for Postoperative Pain in Hip Surgery

NCT06834243 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2026-05-14

No results posted yet for this study

Summary

This retrospective study evaluates the effects of two different administration methods of the Pericapsular Nerve Group (PENG) Block on postoperative pain control, opioid consumption, and recovery in patients undergoing hip surgery.

All patients in the study received:

* PENG block via a catheter
* Patient-Controlled Analgesia (PCA) with tramadol
* Multimodal analgesia, including IV paracetamol and nonsteroidal anti inflammatory drugs (NSAIDs) as rescue analgesia

The study compares two groups:

1. Intermittent Bolus Group: A researcher administered 20 mL of 0.25% bupivacaine every 4 hours.
2. Continuous Infusion Group: A pump delivered 5 mL/hour of 0.25% bupivacaine continuously.

Both groups received the same total volume of local anesthetic over 24 hours. All PENG blocks were performed under ultrasound guidance at the end of surgery. This study aims to determine whether intermittent bolus or continuous infusion PENG block administration leads to better pain control, lower opioid consumption, and improved recovery outcomes.

Conditions

  • Hip Surgery
  • Postoperative Pain Management
  • Pericapsular Nerve Group Block (PENG Block)
  • Regional Anesthesia

Interventions

PROCEDURE

Intermittent Bolus PENG Block

Patients received intermittent bolus administration of the Pericapsular Nerve Group (PENG) Block via a catheter. A researcher manually administered 20 mL of 0.25% bupivacaine every 4 hours over a 24-hour period.

PROCEDURE

Continuous Infusion PENG Block

Patients received continuous infusion of the Pericapsular Nerve Group (PENG) Block via a catheter. A pump delivered 5 mL/hour of 0.25% bupivacaine continuously over a 24-hour period.

Sponsors & Collaborators

  • Namik Kemal University School of Medicine, Tekirdag

    collaborator OTHER

  • Onur Baran

    lead OTHER

Principal Investigators

  • Cavidan Arar, Prof. Dr. · Medical Faculty of Tekirdağ Namık Kemal University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2024-11-15
Completion
2024-11-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834243 on ClinicalTrials.gov